Biological therapies are an effective treatment for a range of immune-mediated inflammatory
diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel …

Abstract The Asia–Pacific Working Group on Inflammatory Bowel Disease was established
in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology …

Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …

Over time, clinicians have become increasingly comfortable embracing the prescription of
biosimilars—highly similar versions of innovator or reference biological agents—for their …

Background & Aims There is evidence that it is safe and effective for patients with
inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original …

The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the
treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with …

Introduction Biosimilars hold the potential to be an integral healthcare component that can
significantly improve affordability and thereby accessibility of the otherwise expensive …

Abstract Background The NOR-SWITCH main and extension trials demonstrated that
switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six …

Abstract Background SB2 (Renflexis®, Merck) and CT-P13 (Inflectra®, Pfizer) are
biosimilars of the reference Infliximab (Remicade®, Janssen) and are approved in Canada …

Background Studies have investigated the efficacy and safety of switching to the biosimilar
infliximab (CT-P13) in patients with inflammatory bowel disease (IBD). However, there is …